UNITEDHEALTH GROUP INCORPORATED (Delaware) (UNH)
UnitedHealth Group Incorporated is a diversified healthcare company based in the United States. It operates primarily through two segments: UnitedHealthcare, which provides health insurance and benefits services, and Optum, which offers health services including pharmacy care, healthcare technology, and information-intensive services. Established in 1977 and headquartered in Minnetonka, Minnesota, UnitedHealth Group is one of the largest healthcare organizations globally, focusing on improving health care access, affordability, and quality.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| September 23, 2025 | $2.21 | 2025-09-15 | 2025-09-15 |
| June 24, 2025 | $2.21 | 2025-06-16 | 2025-06-16 |
| March 18, 2025 | $2.10 | 2025-03-10 | 2025-03-10 |
| December 17, 2024 | $2.10 | 2024-12-09 | 2024-12-09 |
| September 24, 2024 | $2.10 | 2024-09-16 | 2024-09-16 |
Dividends Summary
- UNITEDHEALTH GROUP INCORPORATED (Delaware) has issued 69 dividend payments over the past 21 years
- The most recent dividend was paid 29 days ago, on September 23, 2025
- The highest dividend payed out to investors during this period was $2.21 per share
- The average dividend paid during this period was $0.84 per share.
Company News
Three healthcare stocks - Moderna, Novo Nordisk, and UnitedHealth Group - face potential challenges, with declining revenues, market competition, and ongoing investigations creating uncertainty for investors.
Humana lost a legal challenge against federal government cuts to its Medicare Advantage bonus payments, with a Texas judge upholding the downgrade of its star ratings. This ruling could potentially impact billions in revenue for the company.
Congress members made strategic stock purchases in Q3 2025, focusing on technology, healthcare, and financial sectors, with notable investments in UnitedHealth, JPMorgan, Uber, Advanced Micro Devices, and Palantir Technologies.
Law firm investigating potential claims against Humana regarding alleged misleading statements about medical cost pressures and earnings, with stock price experiencing significant drops following earnings announcements.
Elevance Health reported strong Q2 2024 earnings, with adjusted EPS of $10.12 beating estimates. However, the company saw a decline in medical membership and premium revenues, impacting overall margins. The results were driven by improved product revenues in the CarelonRx business and higher net investment income.
